Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights
March 30, 2023 16:10 ET
|
Fortress Biotech, Inc.
Fortress expects to file a total of three new drug applications in 2023 Record consolidated net revenue of $75.7 million for full-year 2022 FDA accepted for filing the Biologics License Application...
Fortress Biotech to Participate in Two March 2023 Investor Conferences
March 07, 2023 08:00 ET
|
Fortress Biotech, Inc.
MIAMI, March 07, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing...
Helocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
February 16, 2023 08:30 ET
|
Fortress Biotech, Inc.
Results demonstrate the potential benefit of vaccinating donors with Triplex to enhance CMV protective immunity and reduce CMV events in recipients of allogeneic hematopoietic cell transplant ...
Study Published in American Journal of Hematology Demonstrates First Reported Evidence of Safe and Successful Boosting of Cytomegalovirus Vaccine-Specific T Cell Immunity in a Stem Cell Transplant Recipient Via Vaccination of a Donor with Triplex
February 15, 2023 08:30 ET
|
Fortress Biotech, Inc.
Phase 2 clinical trial planned to evaluate efficacy of Triplex-vaccinated donors to enhance protective CMV-specific T cell immunity in stem cell transplant recipients Helocyte, Inc., a subsidiary...
Fortress Biotech Announces Closing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
February 10, 2023 12:50 ET
|
Fortress Biotech, Inc.
MIAMI, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and...
Fortress Biotech Announces Pricing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
February 08, 2023 08:00 ET
|
Fortress Biotech, Inc.
MIAMI, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and...
Fortress Biotech Appoints Lucy Lu, M.D., to its Board of Directors
December 19, 2022 08:00 ET
|
Fortress Biotech, Inc.
MIAMI, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing...
Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin Co. Ltd. to Develop Dotinurad in Additional Territories Including Turkey and the Middle East and North Africa
December 14, 2022 08:00 ET
|
Fortress Biotech, Inc.
MIAMI, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”) (formerly known as UR-1 Therapeutics, Inc.), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”)...
Fortress Biotech to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference
December 06, 2022 08:30 ET
|
Fortress Biotech, Inc.
MIAMI, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and...
Fortress Biotech Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
November 14, 2022 16:01 ET
|
Fortress Biotech, Inc.
Net revenue for the nine months of 2022 increased 17.5% period-over-period to $59.3 million Cosibelimab BLA submission for metastatic and locally advanced cutaneous squamous cell carcinoma expected...